Adaptive Biotechnologies again lifted 2026 revenue guidance, citing continued expansion in its minimal residual disease (MRD) testing business. The company now expects 2026 MRD revenue of $268 million to $278 million, up from a prior range of $260 million to $270 million, driven by strong Q2 performance. Adaptive reported Q2 MRD revenue of $66.2 million, up 33% year over year, and delivered 36,111 ClonoSEQ tests in the quarter—43% higher than a year ago. CEO Chad Robins attributed growth to increased blood-based testing and continued uptake of MRD for serial monitoring rather than only one-time assessments. The update underscores the commercialization momentum for MRD platforms, even as immune medicine revenue declined year over year.